Bristol Myers Squibb (NYSE:BMY – Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16, FiscalAI reports. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 66.57% and a net margin of 15.01%.The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.80 earnings per share. Bristol Myers Squibb updated its FY 2026 guidance to 6.050-6.350 EPS.
Here are the key takeaways from Bristol Myers Squibb’s conference call:
- BMS reaffirmed 2026 guidance and said Q1 results are tracking toward the upper end of ranges after $11.5B in revenue and $1.58 EPS, with ~$11B in cash and $1.1B operating cash flow.
- The growth portfolio gained momentum—portfolio sales were up 9% to ~$6.2B with notable product strength (Breyanzi +53%, Reblozyl +15%, Camzyos nearly doubled) and ELIQUIS up ~13%, supporting diversified near-term revenue drivers.
- Significant pipeline and regulatory progress — iberdomide filing accepted with Breakthrough Therapy designation and a PDUFA date of Aug 17, mezigdomide reported positive Phase III interim data, and iza?bren showed positive Phase III China results while other lifecycle approvals broaden the portfolio.
- Milvexian is a high?impact late?stage program (20,500?patient AFib study) designed for non?inferiority vs apixaban with superiority testing on bleeding; readouts for AFib and secondary stroke prevention are expected late?2026 and management projects substantial commercial upside if successful.
- Opdivo revenue declined ~8% (to ~$2.1B), driven mainly by a U.S. wholesaler inventory drawdown and near?term demand uncertainty, which management says may normalize later in the year.
Bristol Myers Squibb Trading Down 3.9%
BMY traded down $2.35 during trading on Friday, hitting $58.24. 18,358,788 shares of the company’s stock were exchanged, compared to its average volume of 8,930,413. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $62.89. The stock has a 50 day moving average price of $59.56 and a 200 day moving average price of $54.48. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The firm has a market cap of $118.92 billion, a P/E ratio of 16.88, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26.
Bristol Myers Squibb Dividend Announcement
More Bristol Myers Squibb News
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: BMY posted a Q1 beat — $1.58 EPS vs. consensus ~$1.42 and $11.49B revenue — driven by growth drugs and Eliquis outperformance, which supports near?term cash flow. Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales
- Positive Sentiment: Management reiterated FY outlook and emphasized the “growth portfolio” (Breyanzi, Camzyos) and cost?cutting progress as drivers of durable margin improvement. Bristol-Myers Squibb Signals Confident Path After Q1 Call
- Positive Sentiment: Pipeline catalysts could lift long?term growth: Phase III readouts for milvexian (potential Eliquis successor) and Cobenfy (schizophrenia) are highlighted as multi?year drivers. BMS brings the buzz around late-stage readouts amid a so-so Q1
- Neutral Sentiment: Analysts’ consensus price target sits near $61.31, indicating limited upside from current levels absent new positive catalysts. Bristol Myers Squibb Company (NYSE:BMY) Receives $61.31 Consensus PT from Analysts
- Negative Sentiment: FY 2026 guidance (EPS 6.05–6.35; revenue $46.0–47.5B) left the revenue midpoint slightly below the Street, tempering upside after the quarter and contributing to profit?taking. Bristol Myers Squibb Reports First Quarter Financial Results for 2026
- Negative Sentiment: Analysts/coverage notes emphasize the scale of the Eliquis patent cliff (multi?billion dollar risk over coming years), which pressures valuation beyond near?term beats. Thinning revenues: inside the $14bn Eliquis patent cliff
- Negative Sentiment: Bernstein maintained a Hold rating, signaling that some investors and analysts want clearer evidence that growth and pipeline will offset legacy declines. Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Insider Buying and Selling at Bristol Myers Squibb
In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is owned by insiders.
Institutional Investors Weigh In On Bristol Myers Squibb
Several institutional investors and hedge funds have recently modified their holdings of the stock. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter valued at $25,000. Swiss RE Ltd. purchased a new position in shares of Bristol Myers Squibb in the fourth quarter valued at $25,000. JPL Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the third quarter valued at $36,000. Turning Point Benefit Group Inc. purchased a new position in shares of Bristol Myers Squibb in the third quarter valued at $40,000. Finally, Quarry LP purchased a new position in shares of Bristol Myers Squibb in the third quarter valued at $48,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Analysts Set New Price Targets
A number of research firms recently issued reports on BMY. Morgan Stanley restated an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. UBS Group restated a “buy” rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a report on Friday, March 6th. Bank of America lowered their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, Scotiabank reissued a “sector perform” rating and set a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $61.31.
View Our Latest Stock Report on Bristol Myers Squibb
Bristol Myers Squibb Company Profile
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.
Further Reading
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
